Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Non-Current Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $42.2 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 97.24% to $42.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.2 million through Dec 2025, up 97.24% year-over-year, with the annual reading at $42.1 million for FY2025, 49.72% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $42.2 million at Aytu Biopharma, up from $35.8 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $117.7 million in Q4 2021, with the low at $14.4 million in Q1 2024.
  • Average Total Non-Current Liabilities over 5 years is $62.3 million, with a median of $42.2 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities soared 190.88% in 2021, then tumbled 85.37% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $117.7 million in 2021, then dropped by 22.31% to $91.5 million in 2022, then crashed by 62.6% to $34.2 million in 2023, then plummeted by 37.4% to $21.4 million in 2024, then surged by 97.24% to $42.2 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $42.2 million, $35.8 million, and $42.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.